TrimRX | Compounded Semaglutide Latest Research: New Indications, Trials & What’s Coming

Introduction

Semaglutide’s clinical footprint has expanded far beyond diabetes and weight loss. Approved indications now include cardiovascular risk reduction (March 2024 FDA approval based on SELECT) and chronic kidney disease in type 2 diabetes (January 2025 FDA approval based on FLOW). Active phase 3 programs cover MASH (metabolic dysfunction-associated steatohepatitis), Alzheimer’s disease, heart failure with preserved ejection fraction, alcohol use disorder, and substance use disorders.

ESSENCE phase 3 (Newsome 2024 NEJM interim) showed semaglutide 2.4 mg resolved MASH in 62.9% of patients vs 34.3% on placebo at 72 weeks. STEP-HFpEF demonstrated symptomatic improvement in obesity-related heart failure. Multiple smaller trials suggest reduced alcohol consumption and smoking cessation effects.

This article reviews the published trial evidence for each new indication, the pipeline, and what compounded semaglutide users should know about evolving applications.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Did SELECT Show for Cardiovascular Disease?

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults with established cardiovascular disease and BMI ≥27 but without diabetes. Participants were randomized to semaglutide 2.4 mg weekly or placebo and followed for a mean of 39.8 months.

Quick Answer: SELECT (Lincoff 2023, NEJM): 20% reduction in major cardiovascular events; FDA-approved indication March 2024

The primary endpoint, a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, occurred in 6.5% of semaglutide patients vs 8.0% on placebo. That’s a 20% relative risk reduction (hazard ratio 0.80, 95% CI 0.72-0.90, p<0.001). The benefit emerged within the first 12 months and persisted throughout follow-up.

Lincoff et al. published in NEJM November 2023. The FDA expanded Wegovy®’s indication in March 2024 to include cardiovascular risk reduction in adults with established cardiovascular disease and obesity. This was the first GLP-1 cardiovascular indication outside the diabetes population.

What Does FLOW Mean for Kidney Disease?

FLOW enrolled 3,533 people with type 2 diabetes and chronic kidney disease (eGFR 25-75 mL/min/1.73 m² with urine albumin-to-creatinine ratio 100-5000). Participants received semaglutide 1.0 mg weekly or placebo. Median follow-up was 3.4 years.

The primary composite of kidney failure, sustained 50% eGFR decline, kidney death, or cardiovascular death occurred in 18.7% of semaglutide patients vs 23.2% on placebo. That’s a 24% relative risk reduction (HR 0.76, 95% CI 0.66-0.88, p<0.001).

Perkovic et al. published in NEJM May 2024. The FDA approved Ozempic® for chronic kidney disease in type 2 diabetes in January 2025. The benefit appeared at multiple eGFR levels and was independent of glucose control and weight loss, suggesting direct kidney protection.

What Did ESSENCE Show for Fatty Liver Disease?

ESSENCE is the phase 3 trial of semaglutide 2.4 mg weekly in adults with biopsy-confirmed MASH (formerly NASH) and fibrosis stages 2-3. The trial enrolled approximately 800 participants for a 240-week duration with interim 72-week histological analysis.

Newsome et al. presented and published interim ESSENCE data in NEJM in 2024 showing:

MASH resolution without worsening of fibrosis: 62.9% on semaglutide vs 34.3% on placebo (p<0.001)
≥1 stage improvement in fibrosis without worsening MASH: 36.8% on semaglutide vs 22.4% on placebo (p<0.001)

Both endpoints are FDA-recognized for MASH drug approval. Novo Nordisk has filed for FDA approval of semaglutide for MASH, with decision expected in 2025-2026. If approved, semaglutide would join resmetirom (Madrigal’s Rezdiffra®, approved March 2024 based on MAESTRO-NASH) as the only approved MASH therapies.

What’s the Story on Heart Failure with Preserved EF?

STEP-HFpEF (Kosiborod 2023, NEJM) enrolled 529 patients with heart failure with preserved ejection fraction (HFpEF) and BMI ≥30. Semaglutide 2.4 mg weekly improved Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score by 7.8 points more than placebo at 52 weeks. NT-proBNP, six-minute walk distance, and C-reactive protein all improved as well.

STEP-HFpEF DM (Kosiborod 2024, NEJM) confirmed similar benefits in patients with HFpEF and type 2 diabetes. The combined data establish semaglutide as a meaningful therapy for obesity-associated HFpEF, a condition without prior effective treatments beyond SGLT2 inhibitors.

FDA approval for an HFpEF indication has not occurred as of mid-2025, but cardiology guidelines are increasingly recommending GLP-1 therapy for obesity-associated HFpEF based on this evidence base.

What About Alzheimer’s Disease?

EVOKE and EVOKE+ are two phase 3 trials testing oral semaglutide 14 mg daily in early Alzheimer’s disease, with topline results expected in late 2025 or 2026. The hypothesis is based on observational data showing reduced dementia rates in diabetic patients on GLP-1 therapy, plus preclinical data showing reduced neuroinflammation and amyloid accumulation.

A 2024 case-control study in Alzheimer’s & Dementia analyzed 1.7 million electronic health records and found semaglutide use associated with a 40-70% lower risk of Alzheimer’s diagnosis vs other antidiabetic medications. The signal is consistent across multiple cohorts but is not yet randomized trial evidence.

If EVOKE shows benefit, semaglutide could become the first GLP-1 approved for a neurological indication. The current placebo treatment effect on standard Alzheimer’s progression measures is modest, so even small benefits would be clinically meaningful.

What’s the Alcohol and Addiction Research?

Multiple small trials have suggested semaglutide reduces alcohol craving and consumption. A 2023 study in Nature Communications showed reduced ethanol preference in mice and dose-dependent reduction in drinking in early human studies.

The SEMA-AUD trial (NCT05891587), a phase 2 study in adults with alcohol use disorder, is testing semaglutide 2.4 mg weekly against placebo with 24-week outcomes including heavy drinking days. Topline results expected 2025-2026.

For smoking, a 2024 JAMA Network Open analysis showed semaglutide users had higher quit rates than non-users. Mechanistic explanations involve GLP-1 modulation of dopamine reward pathways.

Compounded semaglutide is not approved or recommended for addiction treatment outside of approved indications. The research is promising but premature for off-label addiction prescribing.

What’s Happening in PCOS Research?

Polycystic ovary syndrome is the leading cause of infertility in women of reproductive age and is closely linked to insulin resistance and obesity. Semaglutide trials in PCOS have shown:

A 2024 trial in Cell Reports Medicine showed semaglutide 1.0 mg weekly improved ovulation rates from 23% on placebo to 71% on drug over 32 weeks in women with PCOS
Multiple smaller trials show reduced testosterone, improved menstrual regularity, and reduced hirsutism scores

Semaglutide is not FDA-approved for PCOS but is widely prescribed off-label by reproductive endocrinologists and obesity specialists for PCOS-associated weight and metabolic issues. The TrimRx free assessment quiz captures PCOS as a qualifying comorbidity for weight management therapy.

What About Knee Osteoarthritis?

STEP 9 (Bliddal 2024, NEJM) tested semaglutide 2.4 mg weekly in 407 adults with obesity and knee osteoarthritis. Over 68 weeks, semaglutide produced 13.7% body weight loss and 41.7-point reduction in WOMAC pain score vs 27.5-point reduction on placebo. The pain improvement was clinically meaningful and tracked with weight loss but exceeded what would be predicted from weight loss alone.

This adds to earlier evidence from the IDEA trial (Messier 2013, JAMA) showing weight loss reduces knee OA pain. Semaglutide accelerates that effect. Orthopedic guidelines have begun incorporating GLP-1 therapy as a non-surgical option for obesity-associated knee OA.

Key Takeaway: ESSENCE phase 3: 62.9% MASH resolution at 72 weeks on semaglutide 2.4 mg

What’s the Data on Cancer Prevention?

Multiple observational studies suggest GLP-1 therapy reduces risk of obesity-associated cancers including colorectal, endometrial, and possibly pancreatic and liver cancer. A 2024 JAMA Network Open cohort analysis of 1.65 million people with type 2 diabetes showed semaglutide associated with 15-44% lower incidence across 10 obesity-related cancers vs insulin.

These data are observational and need randomized confirmation. The cardiovascular and kidney trials have shown remarkably consistent class effects, and the cancer signal may prove similarly strong. The thyroid cancer concern from rodent data remains unresolved but human data after 10+ years of GLP-1 use don’t show an elevated thyroid cancer signal.

What’s Next: Oral Semaglutide and Higher Doses

Oral semaglutide for weight loss is in phase 3. OASIS-1 (Knop 2023, Lancet) tested oral semaglutide 50 mg daily and showed 15.1% weight loss at 68 weeks, comparable to injectable. FDA approval for oral semaglutide weight management is expected in 2025-2026.

Higher-dose injectable semaglutide is also being tested. STEP-UP is studying 7.2 mg weekly vs the current 2.4 mg maximum. Higher doses may produce more weight loss but also more side effects. The risk-benefit balance at higher doses is still being defined.

Long-acting once-monthly GLP-1 agonists are in early development. If successful, monthly dosing would simplify adherence and potentially smooth side effects.

What Does All This Mean for Compounded Semaglutide Users?

The drug’s clinical value continues to expand. People taking compounded semaglutide for weight loss are likely also getting cardiovascular, kidney, fatty liver, and possibly cognitive benefits, though these aren’t separately approved indications for compounded products.

The breadth of evidence supports long-term use rather than short courses. The most relevant question for current users isn’t “should I start?” but “should I plan for years of maintenance?” Most clinical evidence now favors continued therapy for metabolic and cardiovascular protection.

TrimRx personalizes treatment plans around your specific health goals and conditions. The free assessment quiz captures cardiovascular history, kidney function status, and other factors that influence long-term planning.

How Is the Regulatory Landscape Changing for GLP-1 Drugs?

The FDA has expanded GLP-1 indications faster than any other drug class in recent memory. Within 2 years (March 2024 to early 2025), semaglutide gained cardiovascular and CKD indications, tirzepatide gained OSA approval, and multiple new indications are pending review for both molecules.

Medicare expansion remains a key policy question. Current statute excludes anti-obesity medications from Part D coverage. Bipartisan legislation has been introduced repeatedly but not passed. The cardiovascular indication for semaglutide and OSA indication for tirzepatide have opened limited Medicare access through specific clinical pathways.

State Medicaid coverage is expanding patchily. As of 2025, about 20 states cover Wegovy through Medicaid. Coverage decisions are increasingly based on cost-effectiveness modeling that includes long-term cardiovascular and metabolic outcomes rather than weight loss alone.

What About Cost Trajectories?

Brand GLP-1 list prices have held relatively flat in the US since launch despite high demand. Eli Lilly’s LillyDirect cash pay program in 2024 introduced the first major price break, offering Zepbound® vials at 30-50% below pen retail. Novo Nordisk has not yet matched with a comparable direct-to-consumer offering for Wegovy.

International pricing differs dramatically. Brand semaglutide in Canada, Germany, and the UK retails for 20-40% of US prices. Patent and manufacturing exclusivity remain in place for both semaglutide and tirzepatide through the late 2020s in most markets.

Generic competition for semaglutide is not expected before 2032 in the US. Until then, brand prices, manufacturer cash-pay programs, and legally compounded preparations are the main supply pathways.

What’s the State of GLP-1 Research in Non-obesity Conditions?

Beyond the indications discussed earlier, GLP-1 drugs are being studied in:

Parkinson’s disease: small phase 2 trials show possible motor symptom improvements
Polycystic kidney disease: early-stage investigation
Inflammatory bowel disease: possible anti-inflammatory benefits
Long COVID: investigated for metabolic and inflammatory components
Autism spectrum disorder: very early data on possible neuropsychiatric effects

Most of these are early-stage exploratory studies, not phase 3 programs. The breadth reflects how widely GLP-1 receptors are expressed across body systems and how broadly GLP-1 modulates inflammation and metabolism.

What Does the Next Decade Likely Look Like for Semaglutide Users?

Several reasonable predictions based on current evidence:

Indications will continue to expand. MASH approval is likely within 1-2 years. Alzheimer’s results from EVOKE may produce another expansion in 2026-2027. Cancer prevention data may eventually drive an indication if randomized trial evidence catches up to observational signals.

Costs will likely drop. LillyDirect set a precedent for direct cash pricing. Novo Nordisk may follow. Compounding will continue under section 503A pending clinical justification.

New molecules will compete. Retatrutide, orforglipron, survodutide, and others may shift the standard of care. Patients on semaglutide today may switch to newer agents over the next 5 years if those agents prove better.

The long-term safety record continues to strengthen. After 10+ years of GLP-1 use at population scale, no new major safety signals have emerged. Long-term effects on cognition, cancer risk, and overall mortality appear net positive.

Bottom line: Alzheimer’s, addiction, and PCOS programs are in active phase 2-3 testing

FAQ

Will Compounded Semaglutide Be Approved for These New Indications?

No. Compounded medications are not FDA-approved for any indication. The brand drugs (Wegovy, Ozempic) receive new indications based on trials. Compounded preparations contain the same active ingredient and produce the same biological effects, but they aren’t separately approved.

Should I Take Semaglutide for Cardiovascular Protection If My BMI Is Low?

Currently, the FDA-approved cardiovascular indication requires BMI ≥27 with established cardiovascular disease. People with normal BMI and cardiovascular disease typically use other proven therapies (statins, antiplatelets, ACE inhibitors, SGLT2 inhibitors).

When Will MASH Approval Come?

Novo Nordisk filed for FDA approval based on ESSENCE interim data. Approval decision is expected in 2025-2026. If approved, semaglutide would become a first-line MASH therapy.

Is Semaglutide Proven for Alzheimer’s?

Not yet. EVOKE phase 3 trials are running with results expected 2025-2026. Observational data is promising but not yet sufficient for clinical recommendations.

Should I Use Semaglutide to Quit Drinking?

Off-label use for addiction is not recommended. Trials are ongoing. If you have alcohol use disorder, evidence-based therapies (naltrexone, acamprosate, behavioral therapy) remain the standard.

Can Compounded Semaglutide Be Prescribed for Kidney Disease?

Compounded semaglutide contains the same active ingredient and produces the same biological effects shown in FLOW. However, compounded medications are prescribed under individual provider discretion, not for specific approved indications. Discuss with a nephrologist if CKD is your primary concern.

What New GLP-1 Drugs Are Coming?

Several next-generation GLP-1 and GLP-1/GIP/glucagon triagonists are in development. Retatrutide (Eli Lilly) showed 24.2% weight loss at 48 weeks in phase 2 (Jastreboff 2023, NEJM) and is in phase 3. CagriSema (cagrilintide + semaglutide, Novo Nordisk) is also in phase 3 with promising early data.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Compounded Semaglutide Latest Research: New Indications, Trials & What’s Coming

Table of Contents